(3R,4S)-Tofacitinib,
1092578-46-5,
CHEMBL457871,
3-((3R,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-{(3R,4S)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile,
Tofacitinib Impurity A,
DTXSID40648965,
BCP12460,
BDBM50273894,
HY-40354D,
ZINC13974878,
ACN-027534,
CS-1109,
RL06156,
SB18653,
SW220133-2,
W-6010,
J-501266,
3-((3R,4S)-3-((1H-Indol-4-yl)(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropane-nitrile,
(3R,4S)-Tofacitinib; 3-((3R,4S)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile; 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)--oxo-, (3R,4S)-,
1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)--oxo-, (3R,4S)-,
Tofacitinib (CP-690550,Tasocitinib),
B1259,